Evotec (NASDAQ:EVO) Shares Gap Up – Here’s Why

Evotec SE (NASDAQ:EVO) gapped up before the market opened on Tuesday . The stock had previously closed at $3.58, but opened at $3.77. Evotec shares last traded at $3.85, with a volume of 32,036 shares.

Evotec Stock Up 10.2 %

The firm has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $4.07. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in shares of Evotec during the 4th quarter worth approximately $27,000. Bank of America Corp DE raised its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. CSS LLC IL bought a new stake in shares of Evotec during the 4th quarter valued at about $50,000. DCF Advisers LLC boosted its stake in Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after purchasing an additional 12,816 shares during the period. Finally, Lighthouse Investment Partners LLC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $166,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.